Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
H14
Study information
Scientific title
Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Lymphoma (Hodgkin's)
Intervention
Patients are randomised to one of two chemotherapy regimens:
1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses.
2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).
Intervention type
Drug
Phase
Not Applicable
Drug names
Primary outcome measures
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/01/1989
Overall trial end date
01/10/1993
Reason abandoned
Eligibility
Participant inclusion criteria
1. Hodgkin's lymphoma stage IIB, III or IV
2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV)
3. Local hisopathological review of diagnosis
4. No medical contraindications to treatment protocols
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/01/1989
Recruitment end date
01/10/1993
Locations
Countries of recruitment
United Kingdom
Trial participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
Sponsor information
Organisation
Cancer Research UK (CRUK) (UK)
Sponsor details
PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom
+44 (0)207 317 5186
kate.law@cancer.org.uk
Sponsor type
Charity
Website
Funders
Funder type
Charity
Funder name
Cancer Research UK
Alternative name(s)
CRUK
Funding Body Type
private sector organisation
Funding Body Subtype
other non-profit
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary